XORTX Therapeutics (XRTX) Non-cash Items (2020 - 2026)
XORTX Therapeutics' (XRTX) quarterly Non-cash Items came in at -$501362.0 in Q1 2026, up 22.12% YoY from -$410561.7 in Q1 2025, and up 28.57% on a QoQ basis from -$701857.0 in Q4 2025.
XORTX Therapeutics (XRTX) Non-cash Items (2020 - 2026) Analysis & Trends
XORTX Therapeutics (XRTX) has 7 years of Non-cash Items data on file, last reported at -$501362.0 in Q1 2026.
- Quarterly Non-cash Items rose 22.12% year-over-year to -$501362.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$2.6 million (down 297.27% YoY) and the FY2025 annual result came in at -$2.8 million, down 175.26% from the prior year.
- Non-cash Items advanced to -$501362.0 in Q1 2026, from -$701857.0 in the prior quarter.
- In the past five years, Non-cash Items ranged from a high of $11.9 million in Q4 2023 to a low of -$3.8 million in Q4 2022.
- A 5-year average of -$126129.9 and a median of -$793519.0 in 2025 frame the typical range for Non-cash Items.
- Annual changes were most pronounced in 2022 — Non-cash Items sank 9976.87% — and 2023, when it jumped 412.41%.
- Tracing XRTX's Non-cash Items over 5 years: stood at -$3.8 million in 2022, then jumped by 412.41% to $11.9 million in 2023, then plunged by 45.48% to $6.5 million in 2024, then plunged by 110.85% to -$701857.0 in 2025, then rose by 28.57% to -$501362.0 in 2026.
- The last three Non-cash Items figures came in at -$501362.0 (Q1 2026), -$701857.0 (Q4 2025), and -$629617.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.77 Bn | 130.92 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.72 Bn | 77.73 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.93 Bn | 59.75 Bn | 1.37 Bn |
| 4 | Moderna | 58.06 Bn | 52.92 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.97 Bn | 36.87 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.53 Bn | 28.22 Bn | 992.69 Mn |
| 7 | BioNTech SE | 27.98 Bn | 9.59 Bn | 668.28 Mn |
| 8 | Insmed | 27.40 Bn | 26.24 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - |
| 10 | XORTX Therapeutics | 2.84 Mn | 2.84 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -501,362.00 |
| Mar 31, 2026 | -501,362.00 |
| Dec 31, 2025 | -701,857.00 |
| Dec 31, 2025 | -701,857.00 |
| Sep 30, 2025 | -629,617.00 |
| Sep 30, 2025 | -629,617.00 |
| Jun 30, 2025 | -793,519.00 |
| Jun 30, 2025 | -793,519.00 |
| Mar 31, 2025 | -643,730.00 |
| Mar 31, 2025 | -643,730.00 |
| Dec 31, 2024 | 6.47 Mn |
| Dec 31, 2024 | 6.47 Mn |
| Sep 30, 2024 | -751,851.00 |
| Sep 30, 2024 | -751,851.00 |
| Jun 30, 2024 | -3.74 Mn |
| Jun 30, 2024 | -3.74 Mn |
| Mar 31, 2024 | 1.70 Mn |
| Mar 31, 2024 | 1.70 Mn |
| Dec 31, 2023 | 11.87 Mn |
| Dec 31, 2023 | 11.87 Mn |